Stock Track | LivaNova Soars 6.79% in Pre-market on Strong Q1 Earnings Beat and Raised Guidance

Stock Track

May 06

LivaNova PLC's stock surged 6.79% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results.

The medical technology company reported quarterly revenue of $362.3 million, beating analyst estimates of $346.1 million and representing a 14.3% increase year-over-year. Adjusted earnings per share came in at $0.98, surpassing the consensus estimate of $0.90.

Furthermore, LivaNova raised its full-year 2026 guidance, now expecting constant-currency revenue growth of 7.0% to 8.0%, up from the previous range of 6.0% to 7.0%. The company also increased its adjusted diluted EPS guidance to $4.20-$4.30 from $4.15-$4.25. The positive results were accompanied by news of FDA premarket approval for its aura6000 System for treating obstructive sleep apnea and the publication of positive 12-month results from the OSPREY clinical trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1153912912"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153912912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153912912?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153912912","market":"nz","top_or_hot":-1,"title":"Stock Track | LivaNova Soars 6.79% in Pre-market on Strong Q1 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>LivaNova PLC's stock surged 6.79% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The medical technology company reported quarterly revenue of $362.3 million, beating analyst estimates of $346.1 million and representing a 14.3% increase year-over-year. Adjusted earnings per share came in at $0.98, surpassing the consensus estimate of $0.90.</p><p>Furthermore, LivaNova raised its full-year 2026 guidance, now expecting constant-currency revenue growth of 7.0% to 8.0%, up from the previous range of 6.0% to 7.0%. The company also increased its adjusted diluted EPS guidance to $4.20-$4.30 from $4.15-$4.25. The positive results were accompanied by news of FDA premarket approval for its aura6000 System for treating obstructive sleep apnea and the publication of positive 12-month results from the OSPREY clinical trial.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LivaNova Soars 6.79% in Pre-market on Strong Q1 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LivaNova Soars 6.79% in Pre-market on Strong Q1 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 20:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LivaNova PLC's stock surged 6.79% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results.</p><p>The medical technology company reported quarterly revenue of $362.3 million, beating analyst estimates of $346.1 million and representing a 14.3% increase year-over-year. Adjusted earnings per share came in at $0.98, surpassing the consensus estimate of $0.90.</p><p>Furthermore, LivaNova raised its full-year 2026 guidance, now expecting constant-currency revenue growth of 7.0% to 8.0%, up from the previous range of 6.0% to 7.0%. The company also increased its adjusted diluted EPS guidance to $4.20-$4.30 from $4.15-$4.25. The positive results were accompanied by news of FDA premarket approval for its aura6000 System for treating obstructive sleep apnea and the publication of positive 12-month results from the OSPREY clinical trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIVN","symbol_name":"LivaNova PLC","start_time":0,"source_url":"","article_id":"1153912912","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153912912","pubTimestamp":1778070048,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LivaNova PLC's stock surged 6.79% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results.The medical technology company reported quarterly revenue of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LIVN":"LivaNova PLC"},"translate_title":"个股追踪|LivaNova盘前飙升6.79%，因Q1盈利强劲且指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":1},"content_text":"LivaNova PLC's stock surged 6.79% in pre-market trading on Wednesday, following the release of its first-quarter 2026 financial results.The medical technology company reported quarterly revenue of $362.3 million, beating analyst estimates of $346.1 million and representing a 14.3% increase year-over-year. Adjusted earnings per share came in at $0.98, surpassing the consensus estimate of $0.90.Furthermore, LivaNova raised its full-year 2026 guidance, now expecting constant-currency revenue growth of 7.0% to 8.0%, up from the previous range of 6.0% to 7.0%. The company also increased its adjusted diluted EPS guidance to $4.20-$4.30 from $4.15-$4.25. The positive results were accompanied by news of FDA premarket approval for its aura6000 System for treating obstructive sleep apnea and the publication of positive 12-month results from the OSPREY clinical trial.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}